Intragenic homozygous deletions of MTS1 gene in gastric cancer in Taiwan

Japanese Journal of Cancer Research

Volumn 87, Issue 10, 1996, Pages 1052-1055

  Wu, Ming Shiang ^a   Lin, Ya Wen ^a   Sheu, Jin Chuan ^a   Wang, Hsiu Po ^a   Wang, Jin Town ^a   Shun, Chia Tung ^a   Lee, Wei Jei ^a   Wang, Teh Hong ^a   Lin, Jaw Town ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Gastric adenocarcinoma; Loss of heterozygosity; Microsatellite markers; MTS1 gene; MTS2 gene

Indexed keywords

ARTICLE; CHROMOSOME 9P; CHROMOSOME SATELLITE; CONTROLLED STUDY; DELETION MUTANT; EXON; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUTATION RATE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTHERN BLOTTING; STOMACH ADENOCARCINOMA; STOMACH CANCER; TAIWAN; TUMOR SUPPRESSOR GENE;

EID: 0029826439     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1996.tb03109.x     Document Type: Article

References (25)

1. Hunter, T. and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79, 573-582 (1994).
2. Serrano, M., Hannon, G. J. and Beach, D. H. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/Cdk4. Nature, 366, 704-707 (1993).
3. Kamb, A., Gruis, N., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S., Stockert, E., Day, R., III, Johnson, B. and Skolnick, M. A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436-440 (1994).
4. Nobori, T., Miura, K., Wu, D., Loüs, A., Takabayashi, K. and Carson, D. Deletions in the cyclin-dependent kinase 4 inhibitor gene in multiple human cancers. Nature, 368, 753-756 (1994).
5. Okamoto, A., Demetrick, D. J., Spillare, E. A., Hagiwara, K., Hussuin, S. P., Bennett, W. P., Forrester, K., Gerwin, B., Serrano, M., Beach, D. H. and Harris, C. C. Mutations and altered expression of p16INK4 in human cancer. Proc. Natl. Acad. Sci. USA, 91, 11045-11049 (1994).
6. Jen, J., Harpa, W., Bigner, S. H., Bigner, D. D., Papadopoulos, N., Markowitz, S., Willson, J. K. V., Kinzler, K. W. and Vogelstein, B. Deletion of p16 and p15 genes in brain tumors. Cancer Res., 54, 6353-6358 (1994).
7. Washimi, O., Nagatake, M., Osada, H., Ueda, R., Koshikawa, T., Seki, T., Toshitada, T. and Takahashi, T. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res., 55, 514-517 (1995).
8. Yoshida, S., Todoroki, T., Ichikawa, Y., Hanai, S., Suzuki, H., Hori, M., Fukao, K., Miwa, M. and Uchida, K. Mutations of p16INK4/CDKN2 and p15INK4B/MTS2 genes in biliary tract cancers. Cancer Res., 55, 2756-2760 (1995).
9. Schmidt, E. E., Ichimura, K., Reifenberger, G. and Collins, V. P. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastoma. Cancer Res., 54, 6321-6324 (1994).
10. Mori, T., Miura, K., Aoki, T., Nishihira, T., Mori, S. and Nakamura, Y. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res., 54, 3396-3397 (1994).
11. Zhou, X., Tarmin, L., Yin, J., Jiang, H. Y., Suzuki, H., Rhyu, M. G., Abraham, J. M. and Meltzer, S. J. The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene, 9, 3737-3741 (1994).
12. Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hrubam, R. H., Yeo, C. J. and Kern, S. E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet., 8, 27-32 (1994).
13. Hayashi, N., Sugimoto, Y., Tsuchiya, E., Ogawa, M. and Nakamura, Y. Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4I (cyclin-dependent kinase 4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem. Biophys. Res. Commun., 202, 1426-1430 (1994).
14. Cairns, P., Mas, L., Merlo, A., Lee, D. J., Schwab, D., Eby, Y., Tokino, K., van der Riet, P., Blaugrund, J. E. and Sidransky, D. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science, 265, 415-416 (1994).
15. Spruck, C. H., III, Gonzalez-Zulueta, M., Shibata, A., Gonzales, F., Tsai, I. C. and Jones, P. J. p16 gene in uncultured tumors. Nature, 370, 183-184 (1994).
16. Marx, J. New tumor suppressor may rival p53. Science, 264, 344-345 (1994).
17. Marx, J. A challenge to p16 gene as a major tumor suppressor. Science, 264, 1846 (1994).
18. Tahara, E. Genetic alterations in human gastrointestinal cancers: the application to molecular diagnosis. Cancer, 75, 1410-1417 (1995).
19. Sakata, K., Tamura, G., Maesawa, C., Suzuki, Y., Terashima, M., Satoh, K., Eda, Y., Suzuki, A., Sekiyama, S. and Satodate, R. Loss of heterozygosity on the short arm of chromosome 9 without p16 gene mutation in gastric carcinomas. Jpn. J. Cancer Res., 86, 333-335 (1995).
20. Igaki, H., Sasaki, H., Tachimori, Y., Kato, H., Watanabe, H., Kimura, T., Harada, Y., Sugimura, T. and Terada, M. Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract. Cancer Res., 55, 3421-3423 (1995).
21. Lin, J. T., Wu, M. S., Shun, C. T., Lee, W. J., Sheu, J. C. and Wang, T. H. Occurrence of microsatellite instability in gastric carcinoma is associated with enhanced expression of erbB-2 oncoprotein. Cancer Res., 55, 1428-1430 (1995).
22. Lauren, P. The two histological main types of gastric carcinoma diffuse and so-called intestinal type carcinoma. Acta Pathol Microbiol. Scand., 64, 31-49 (1965).
23. Cairns, P., Polascik, T. J., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Herath, J., Jenkins, R., Westra, W., Rutter, J. L., Buckler, A., Gabrielson, E., Tockman, M., Cho, K. R., Hedrick, L., Bova, C. S., Isaacs, W., Koch, W., Schwab, D. and Sidransky, D. Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nat. Genet., 11, 210-212 (1995).
24. Cheng, J. Q., Jhanwar, S. C., Klein, W. M., Bell, D. W., Lee, W. C., Altomare, D. A., Nobori, T., Olopade, O. I., Buckler, A. J. and Testa, J. R. p16 alterations and deletion mapping of 9p21-22 in malignant mesothelioma. Cancer Res., 54, 5547-5551 (1994).
25. Li, Y. J., Hoang-Xuan, K., Delattre, J. Y., Poisson, M., Thomas, G. and Hamelin, R. Frequent loss of heterozygo-sity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene, 11, 597-600 (1995).